Are You Confident of the Diagnosis?
What to be alert for in the history
Most patients develop a sudden onset of fever and sore throat and appear ill. Associated symptoms include headache, malaise, lymphadenopathy, chills, abdominal pain, nausea, vomiting, anorexia, and myalgias. The erythematous eruption appears 1 to 4 days following the onset of symptoms.
Characteristic findings on physical examination
The characteristic exanthem of scarlet fever consists of blanchable, confluent, erythematous macules and patches as well as minute papules that impart a dry, rough, sandpaper-like texture to the skin. It initially appears on the upper trunk and axillae then generalizes over days, spreading to the lower extremities last and sparing the palms and soles. There is accentuation in the flexural surfaces and dependent regions such as the buttocks.
Facial flushing with circumoral pallor is common.
Pastia’s lines refer to the accentuation of erythema and linear petechiae in the skin folds. They tend to appear prior to the generalized eruption and may persist through the desquamative phase. Petechiae (Forschheimer spots) and erythematous macules may be present on the soft palate. Early in the course of infection, prominent, edematous papillae on the tongue are coated with a thick white membrane (“white strawberry tongue”). Within several days, a brightly erythematous tongue with prominent papillae (“red strawberry tongue”) appears as the membrane sloughs off.
The rash remits within 7 to 10 days and is followed approximately 1 week later by a fine, superficial desquamation especially marked in the skin flexures, face, palms, and soles (Figure 1). The desquamation may continue for up to 6 weeks. Depending on the severity of the illness, patients may develop late sequelae, such as Beau’s lines in the nails, and experience telogen effluvium, 3 to 4 months following infection.
Expected results of diagnostic studies
Diagnosis can usually be made on clinical grounds Leukocytosis with a left shift is almost always present, and nasopharyngeal cultures positive for group A streptococci are confirmatory. A rapid group A streptococcus antigen test can be done and is often more convenient, although not as sensitive as a traditional culture. If the rapid test is positive, a confirmatory culture is unnecessary whereas a negative or equivocal result warrants a nasopharyngeal culture.
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are also elevated. Other laboratory tests that support the diagnosis include detection of antistreptolysin O (ASO), antihyaluronidase, antifibrinolysin, and anti-DNase B antibodies, although these are not specific to scarlet fever and are late findings. Mild albuminemia and hematuria may occur early in the infection, and urinalysis and liver function tests are helpful in assessing possible complications. Blood cultures are rarely positive in uncomplicated disease.
Biopsy is rarely warranted but specimens demonstrate engorged capillaries and dilated lymphatic vessels, most commonly in a perifollicular distribution. There is edema and a sparse polymorphonuclear perivascular infiltrate. There may be focal areas of hemorrhage. During the desquamative phase, epidermal spongiosis and prominent parakeratosis are present.
The differential diagnosis of scarlet fever includes Kawasaki disease, toxic shock syndrome (TSS), staphylococcal scalded skin syndrome (SSSS), rubella, rubeola, mononucleosis, fifth disease, acute lupus erythematosis, juvenile arthritis, other viral exanthems, and drug reactions. Similar cutaneous findings can be seen with pharyngeal infections associated with Staphylococcus aureus, Arcanobacterium haemolyticum, Haemophilus influenzae, and Clostridium species.
The rash in fifth disease may resemble that seen in scarlet fever but it is rarely generalized, and the child appears clinically well.
In rubella and rubeola, the eruption progresses in a cephalocaudad spread rather than beginning on the trunk. Additionally, the triad of cough, coryza, and conjunctivitis is characteristic of rubeola.
Kawasaki disease is an important differential due to the high incidence of long-lasting cardiac sequelae if not treated appropriately. Similarly to scarlet fever, desquamation of the fingers, palms, and soles occurs in a majority of the patients 1 to 2 weeks following the onset of the fever. Asian children, most commonly in Japan, are affected. It rarely occurs in children older than 4 years of age.
Other bacteria-associated syndromes such as TSS and SSSS can be differentiated by hemodynamic instability and the sheet-like desquamation that occurs early in the course of disease, respectively. Tissue biopsy and direct immunofluorescence is helpful in further differentiating SSSS.
The various noninfectious diseases that may mimic the signs of scarlet fever should be considered and can usually be differentiated with a thorough history (ie, cutaneous drug eruption) and careful laboratory workup.
Who is at Risk for Developing this Disease?
Young children between 1 to 10 years old are most frequently affected, since by the age of 10 most develop antibodies to the pathogenic toxins, although adults may rarely be affected. The infection is most common in the late fall, winter, and spring in cooler climates.
What is the Cause of the Disease?
Scarlet fever is a toxin-mediated infection caused by the group A beta-hemolytic streptococcus (GAS) Streptococcus pyogenes. Several microbiologic factors are known to confer antigenicity and virulence to S pyogenes. Since 1933, numerous Lancefield groups have been identified, from A-T, based on the antigenic carbohydrate constituents of the bacterial cell wall. GAS is also subdivided based on the expression of M and T surface antigens.
The M-protein antigen, which is also expressed by Lancefield groups C and G, is the main virulence factor. M proteins are extracellular surface antigens that may behave like superantigens, interfering with antibody binding, complement-mediate opsinization, as well as phagocytosis by polymorphonuclear leukocytes. Currently, there are over 80 M protein types of GAS described, with various strains associated with nonsupportive poststreptococcal sequelae.
Acute rheumatic fever (ARF) is associated with M-types 1,3,5,6,18. Acute poststreptococcal glomerulonephritis (APSGN) is associated with M-types 1-4, 12, 14 (ie, nephritogenic strains). In humans, the quantity of M protein produced by the offending strain decreases throughout the course of the disease as well as with prolonged carriage, which may explain why scarlet fever is rarely seen in adults since they are likely to come into contact with the various antigens starting early in life.
The streptococcal pyrogenic (erythrogenic) exotoxins (SPE) A, B, and C are responsible for the characteristic rash. In addition, they induce lymphocyte blastogenesis, potentiate endotoxin-induced shock, produce fever, decrease antibody production, and act as superantigens. SPEA- and B-producing strains of GAS have been associated with severe cases of scarlet fever and more recently, with streptococcal toxic shock syndrome. The mechanism of SPEA is not fully understand as of yet, but it is significant in that quantities of this exotoxin produced by GAS strains are known to vary tremendously from decade to decade.
The toxins elicit a delayed-type hypersensitivity, thus requiring prior antigenic exposure for the disease to occur. This explains why scarlet fever rarely affects infants since they have not yet been exposed to the exotoxins necessary to produce anti-toxin antibodies.
Scarlet fever most commonly occurs following streptococcal pharyngitis or tonsillitis although other infectious foci such as the skin, soft tissue, surgical wounds (ie, surgical scarlet fever), burns, pelvic organs (ie, puerperal scarlet fever), and food-borne illness are also potential sources.
Systemic Implications and Complications
Complications of scarlet fever include otitis media, sinusitis, pneumonia, bacteremia, osteomyelitis, meningitis, arthritis, erythema nodosum, hepatitis, acute poststreptococcal glomerulonephritis, and acute rheumatic fever. APSGN and ARF occur approximately 10 days following pharyngeal infection.
Systemic antibiotic therapy with penicillin is the treatment of choice for scarlet fever. Treatment is important in terms of quelling the symptoms, decreasing the spread to contacts, as well as avoiding future complications such as ARF and APSGN. Additionally, timely treatment within the first few days of infection is extremely important since ARF and APSGN are manifested shortly after infection and can have lasting consequences.
Treatment with antibiotics after the development of ARF and APSGN appears futile since these are immune-complex-mediated syndromes occurring post-infection. Petrolatum-based emollients are recommended for the desquamative eruption. Oral antihistamines, such as diphenhydramine or hydroxyzine, may be used if there is associated pruritus.
Optimal Therapeutic Approach for this Disease
First-line therapy: benzathine penicillin G IM in a single dose or penicillin VK orally for 10 days.
Second-line therapy: amoxicillin or first-generation cephalosporins orally for 10 days may alternatively be used.
Penicillin-allergic patients: Erythromycin orally for 10 days.
In the event that the physical or laboratory findings do not correlate with the diagnosis, further workup including bacterial and viral cultures/serologies and appropriate therapy is warranted.
Early diagnosis and completion of appropriate antibiotic therapy are essential to treating the infection and preventing any potential complications. With timely intervention the prognosis is excellent; most patients recover in less than 1 week and experience resolution of the cutaneous manifestations within several weeks without any lasting sequelae. Patients are recommended to follow up with their physician to ensure resolution of the primary infection and to evaluate for any signs of rheumatic fever or other complications. Urinalysis should also be done at follow-up to screen for the development of glomerulonephritis.
Unusual Clinical Scenarios to Consider in Patient Management
With the advent of antibiotic therapy, scarlet fever is no longer the significant cause of morbidity and mortality that it was historically. It usually follows a benign course with no long-term sequelae. Recognizing and treating the infection in a timely manner is essential to prevent rheumatic fever and/or poststreptococcal glomerulonephritis. Of note, it appears that acute guttate psoriasis (AGP), a nonsuppurative sequela of GAS pharyngitis, may confer protection against ARF and APSGN as there has been no reported evidence of the co-existence of these three poststreptococcal complications.
In the very rare circumstance that patients experience unlikely morbidity, it will likely be secondary to suppurative complications such as peritonsillar abscess formation, pneumonia, or meningitis. If severe odynophagia related to the pharyngitis develops, monitor for dehydration and nutritional status if the patient is unable to swallow. Extremely rarely, septic shock with multi-organ failure has been reported. In any of the above clinical scenarios, close in-patient treatment including supportive care is warranted.
What is the Evidence?
Berk, D, Bayliss, S. “MRSA, staphyloccocal scalded skin syndrome, and other cutaneous bacterial emergencies”. Pediatric Ann. vol. 39. 2010. pp. 627-33. (A review of the important pediatric bacterial skin infections and specific evaluation and treatment parameters.)
Shulman, ST, Tanz, RR. “Group A streptococcal pharyngitis and immune-mediated complications: from diagnosis to management”. Expert Rev Anti Infect Ther. vol. 8. 2010. pp. 137-50. (GAS pharyngitis from its epidemiology to diagnosis and proposed strategies for management including selective testing to avoid unnecessary testing of viral-like syndromes (cough and rhinorrhea) and appropriate management of immune-mediated sequelae such as ARF and APSGN.)
Manders, SM. “Toxin-mediated streptococcal and staphylococcal disease”. J Am Acad Dermatol. vol. 39. 1998. pp. 383-98. (Understanding the basic science and pathophysiology of how toxins and superantigens lead to the various toxin-mediated diseases and their clinical presentations.)
Krishnamurthy, K, Walker, A, Gropper, G, Hoffman, C. “To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of Group A streptococcal infection”. J Drugs Dermatol. vol. 9. 2010. pp. 241-50. (The role of streptococcus in the immunopathogensis of guttate psoriasis and pityriasis rosea as well as the risk of developing scarlet fever and other poststreptococcal sequelae. It is postulated that streptococcal-associated guttate psoriasis may confer protection against more severe poststreptococcal sequelae such as ARF and APSGN.)
Lancefield, RC. “Current knowledge of type-specific M antigens of group A streptococci”. J Immunol. vol. 89. 1962. pp. 307-13. (The virulence of M-proteins in type-specific antibody production in GAS.)
Robinson, JH, Kehoe, MA. “Group A streptococcal M proteins: virulence factors and protective antigens”. Immunol Today. 1992. pp. 362-7. (A review of the streptococcal M proteins and how they mediate varied streptococcal pathogenicity; 50 years after their initial classification, they still remain at the forefront of the clinicopathologic investigation.)
Barsumian, EL, Schlievert, PM, Watson, DW. “Nonspecific and specific immunological mitogenicity by group A streptococcal pyrogenic exotoxins”. Infect Immun. vol. 22. 1978. pp. 681-8. (Studies in murine and rodent models demonstrated that SPE types A, B, and C induced varied lymphocyte proliferation and responsiveness depending on the stimulation and target tissue.)
Gerber, MA, Baltimore, RS, Eaton, CB, Gewitz, M, Rowley, AH, Shulman, ST. “Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics”. Circulation. vol. 119. 2009. pp. 1541-51. (Timely and accurate diagnosis and treatment of GAS tonsillopharyngitis is critical in preventing ARF. Patients with a history of acute rheumatic fever will need lifelong secondary prophylaxis to prevent recurrences after subsequent GAS infection.)
Bialacki, C, Feder, HM, Grand-Kels, JM. “The six classic childhood exanthems: a review and update”. J Am Acad Dermatol. vol. 21. 1989. pp. 891-903. (This review discusses the epidemiology, etiology, clinical manifestations, histologic and laboratory findings, differential diagnosis, treatment, and prevention of several classic childhood exanthems.)
Sandrini, J, Beucher, AB, Kouatchet, A, Lavigne, C. “Scarlet fever with multisystem organ failure and hypertrophic gastritis”. Rev Med Interne. vol. 30. 2009. pp. 456-9. (Scarlet fever is primarily a diagnosis of children, however; it can occur in adults as in this case report of a 62-year-old female who presented with septic shock and multiple organ failure. A positive sick contact, sand paper rash, and elevated ASO confirmed the diagnosis, and the patient was successfully treated with cefotaxime and amoxicillin.)
As infections with severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) continue to increase, there has been a concurrent increase in news and data, both accurate and inaccurate. Therefore, we have undertaken a review of a considerable amount of this information, and attempted to clarify some of the most recurrent misconceptions.
For example, “coronavirus” is not the appropriate identifier for the cause of the current infection causing epidemics in >40 countries. Coronavirus is the name of a family of viruses, which cause infections in humans and animals.1,2 The current outbreak is caused by a strain of coronavirus that has been named SARS-Cov-2; the constellation of respiratory symptoms caused by this virus is called Coronavirus Disease 2019 (COVID-19).3
1. COVID-19 is a pandemic.
Although the World Health Organization (WHO) has avoided deeming the virus a pandemic, WHO director-general Tedros Adhanom Ghebreyesus said, “This virus has pandemic potential. This is not a time for fear. This is a time for taking action to prevent infection and save lives now.” A pandemic is described as an epidemic that has progressed to a global scale. The term epidemic is applied for the case of an infection that spreads more rapidly than expected, over a large geographic area.5
2. You can get COVID-19 from products shipped from China.
The United States Centers for Disease Control and Prevention has not found any evidence to suggest that animals or animal products imported from China pose a risk for spreading COVID-19 in the United States.6 While it may be possible that a person can get COVID-19 by touching a surface or object that has the viral particles on it and then touching their own mouth, nose, or eyes, there has been no evidence to support this as the main way the virus spreads. In fact, one study reported that while the virus may live on surfaces for up to 9 days, “Data on the transmissibility of coronaviruses from contaminated surfaces to hands were not found. However, it could be shown with influenza A virus that a contact of 5 [seconds] can transfer 31.6% of the viral load to the hands.”7
3. Any cough-based illness is COVID-19.
It is important to remember that in the United States, it is still flu season, and although it may be wrapping up, it can last through May.8 Further, there are several families of viruses that cause respiratory symptoms; these viruses (eg, rhinoviruses, adenoviruses, respiratory syncytial virus, human parainfluenza viruses) are the cause of the common cold, and circulate year-round.9,10
When is a cough concerning? If you feel sick with cough, fever and difficulty breathing, and have been in close contact with a person known to have COVID-19, or if you live in or have recently traveled from an area with ongoing spread of COVID-19.6
4. Community spread means anyone, anywhere can get the infection at any time.
The term community spread is used to describe a situation wherein the exact source of an infection cannot be identified.11 This commonly occurs in the setting of an epidemic: once the cases of an infection reach a certain point, a person may become infected without typical risk factors such as travel to an endemic area, or a person has close-contact with a sick person. In this situation, one may not know when or where they encountered an infected individual. This person may also not yet know they are ill, as they may still be in an incubation or asymptomatic stage of the illness. However, contact is still a requisite for transmission, knowingly or unknowingly. Community spread of infections can be ameliorated through the practice of hand hygiene, and staying home when you feel unwell.6,12
5. Everyone who gets infected with SARS-CoV-2 will die or conversely, only elderly, sick people will die.
Although the majority of cases that result in death are among the elderly, and individuals with chronic health conditions, COVID-19 has affected mostly all age groups, as well as people with no underlying diseases. There have been no deaths reported among children aged <9 years, who represent only 1% of all cases of infection.13 Individuals aged 10 to 19 years demonstrate a similar incidence, and those aged 20 to 29 years account for roughly 8% of cases.14 People aged 30 to 79 years, however, account for 87% of cases.13
The fatality rate for COVID-19 is also skewed toward the elderly: people aged 70 to 79 years have a fatality rate of 8%, compared with 14.8% among those aged >80 years.13 People with any underlying comorbidity have a higher fatality rate.14 In addition, reports indicate more people of the male sex have been infected; they have also more often presented with more severe infection, and have had higher death rates.14
6. COVID-19 is more transmissible/deadlier than the flu.
This is tricky. Such statements can seem true if one is only looking at certain pieces of data; but data needs context. For example, the case fatality rate is frequently reported as being higher than that of the flu; however, it has already been demonstrated that fatality rates vary substantially across patient populations. Moreover, comparing a rate of one infection to another when the factors that influence that rate (number of individuals infected and number of fatalities) are so significantly different is cumbersome. Seasonal influenza has a fatality rate of <1%,15 compared with the roughly 2% fatality rate currently reported for SARS-CoV-2. However, any subgroup analyses (eg, individuals who have died) of the roughly 35 million annual cases of the flu will, more often than not, mathematically find a smaller number compared with an analysis of the roughly 114,000 cases of COVID-19.16
However, current data on the transmissibility of SARS-CoV-2 are more reliable in that calculations definitively take into account more variables.17 These data demonstrate that this infection is slightly more transmissible than the flu; preventive measures, however, are the same. For this reason, all major health organizations, government officials, and even mass transit systems stress the importance of washing your hands frequently, coughing/sneezing into the crook of your elbow, and staying home when ill.6,12
7. Facial masks will keep you from getting sick.
The use of facial masks as a preventive measure for COVID-19 is not presently recommended for the general public.18 Healthcare workers who have direct contact with known cases of SARS-CoV-2 are recommended to use an N95 respirator mask, in conjunction with appropriate gowning and gloving techniques, and only in the hospital/clinic setting.18,19 The N95 filtering facepiece respirator functions by removing particles from the air as the individual breathes through the mask.19 Unlike these, other facemasks are only effective at preventing one from inhaling large respiratory droplets. The use of a non-N95 facemask is effective in preventing a person who is feeling unwell, or has a cough/sneeze-based illness from spreading an ongoing infection.
8. You should not travel internationally, at all.
The CDC issues travel recommendations for several infectious diseases, including COVID-19.20 A Warning Level 3 indicates avoidance of all nonessential travel to a given location. An Alert Level 2 advises that people with chronic medical conditions and older adults should avoid travel to such locations. Watch Level 1 means that the CDC does not recommend cancelling travel to such places. Due to the circulation and air filtration system on airplanes, the risk for infection transmission is low; the CDC does, however, recommend conscientious hand hygiene in this case.
Cruise ships put large numbers of people, potentially from a number of countries around the world, in frequent and close contact with each other; therefore the CDC strongly recommends frequent hand washing and avoidance of touching your face, and staying in your cabin and notifying the onboard medical center immediately if you feel unwell.
9. Flu or pneumonia vaccines will also help prevent COVID.
There are insufficient data to support the advocacy of the influenza or pneumococcal vaccines to prevent COVID-19.21 While these 2 illnesses have similar symptomology to COVID-19, the vaccines are formulated to be active specifically against the influenza virus and streptococcal bacteria, neither of which contribute to COVID-19. However, it is highly recommended that everyone who is indicated to receive either vaccine does so because it may aid in simplifying the evaluation of potential SARS-CoV-2 infections.21,22
10. Heat will kill the virus.
Although a few high-ranking government officials have alluded to the possibility that high temperatures will kill the virus, there is not presently enough evidence to state this with scientific certainty. While the rate of most viral infections decreases during the summer months as a result of higher temperatures and humidity, there are 2 important caveats: people are less likely to be in close quarters with each other for lengthy periods, and although countries in the northern hemisphere are entering warmer months, the opposite is true for countries in the southern hemisphere.23 Further, previous experience with and research on the other Coronavirus epidemics (SARS and MERS) demonstrated that this family of viruses may have little problem surviving in warmer climates.23
- Peiris JSM. Coronaviruses. In: Greenwood D, Barer M, Slack R, Irving W, eds. Medical Microbiology: A Guide to Microbial Infections. 18th ed. Elsevier; 2012:587-593.
- Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23.
- The World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. Updated February 11, 2020. Acessed March 6, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen
- Nebehay S, Shields M. “Fatal mistake” for countries to assume they won’t get coronavirus -WHO chief. Reuters. Published February 27, 2020. Accessed March 6, 2020.
- Grennan D. What is a pandemic? [published online March 5, 2019]. JAMA. doi:10.1001/jama.2019.0700
- Centers for Disease Control and Prevention. How COVID-19 spreads. Updated March 4, 2020. Accessed March 6, 2020. https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html
- Kampf G, Todt D, Pfaender S, Steinmann E. Persistance of coronaviruses on inanimate surfaces and their inactivation with biocidal agents [published online February 6, 2020]. J Hosp Infect. doi:10.1016/j.jhin.2020.01.022
- Centers for Disease Control and Prevention. The flu season. Updated July 12, 2018. Accessed March 6, 2020. https://www.cdc.gov/flu/about/season/flu-season.htm
- National Institutes of Health. Understanding a common cold virus. Updated April 13, 2019. Accessed March 6, 2020. https://www.nih.gov/news-events/nih-research-matters/understanding-common-cold-virus
- Centers for Disease Control and Prevention. Common colds: protect yourself and others. Updated February 11, 2019. Accessed March 6, 2020. https://www.cdc.gov/features/rhinoviruses/index.html
- Centers for Disease Control and Prevention. CDC confirms possible instance of community spread of COVID-19 in U.S. Updated February 26, 2020. Accessed March 6, 2020. https://www.cdc.gov/media/releases/2020/s0226-Covid-19-spread.html
- Canadian Centre for Occupational Health and Safety. Good hygiene practices-reducing the spread of infections and viruses. Updated March 6, 2020. Accessed March 6, 2020. https://www.ccohs.ca/oshanswers/diseases/good_hygiene.html
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China [published online February 24, 2020]. JAMA. doi:10.1001/jama.2020.2648
- Guan W, Ni Z, Hu Y, et al. Clinical chartacteristics of coronavirus disease 2019 in China [published online February 28, 2020]. N Engl J Med. doi:10.1056/NEJMoa2002032
- Centers for Disease Control and Prevention. Disease burden of influenza. Updated January 10, 2020. Accessed March 6, 2020. https://www.cdc.gov/flu/about/burden/index.html
- Johns Hopkins. Coronavirus COVID-19 global cases. Updated March 6, 2020. Accessed March 6, 2020. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
- Swerdlow DL, Finelli L. Preparation for possible sustained transmission of 2019 Novel Coronavirus: lessons from previous epidemics [published online February 11, 2020]. JAMA. doi:10.1001/jama.2020.1960
- The World Health Organization. Coronavirus disease (COVID-19) advice for the public: when and how to use masks. Updated March 6, 2020. Accessed March 6, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public
- Centers for Disease Control and Prevention. Frequently asked questions about personal protective equiptment. Updated February 29, 2020. Accessed March 6, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/respirator-use-faq.html
- Centers for Disease Control and Prevention. Travel: frequently asked questions and answers. Updated March 3, 2020. Accessed March 6, 2020. https://www.cdc.gov/coronavirus/2019-ncov/travelers/faqs.html
- Yale Medicine. COVID-19 (Coronavirus Disease 2019). Accessed March 6, 2020. https://www.yalemedicine.org/conditions/covid-19/
- University of Chicago Medicine. COVID-19: what we know so far about the 2019 novel coronavirus. Published on February 13, 2020. Accessed March 6, 2020. https://www.uchicagomedicine.org/forefront/prevention-and-screening-articles/wuhan-coronavirus
- Le Page M. Will heat kill the coronavirus?. New Scientist. 2020;245(3270):6-7.
This article originally appeared on Medical Bag